Skip to main content
Premium Trial:

Request an Annual Quote

Genetic Technologies Settles IP Dispute with Genesis Genetics Institute

NEW YORK (GenomeWeb News) – Genetic Technologies today announced it has settled with Genesis Genetics Institute over GTG's patent covering its non-coding DNA technology.

GTG sued Detroit-based Genesis Genetics in September in US District Court Eastern District of Michigan, Southern Division, alleging Genesis Genetics infringed on US Patent No. 5,612,179 which was assigned by an entity called Genetype AG to GTG.

The patent is at the center of a number of lawsuits that GTG has leveled at competitors alleging infringement, and in July it settled with Reproductive Genetics Institute over similar litigation. That followed a deal between GTG and Bioscientia Institute for Medical Diagnostics in late June to settle a dispute over the '179 patent.

Terms of the settlement announced today were not disclosed.

On Friday, GTG said that New York has issued a Clinical Laboratory Permit to the firm, allowing it to offer its BREVAGen test to residents of the state.

The Scan

New Study Investigates Genomics of Fanconi Anemia Repair Pathway in Cancer

A Rockefeller University team reports in Nature that FA repair deficiency leads to structural variants that can contribute to genomic instability.

Study Reveals Potential Sex-Specific Role for Noncoding RNA in Depression

A long, noncoding RNA called FEDORA appears to be a sex-specific regulator of major depressive disorder, affecting more women, researchers report in Science Advances.

New mRNA Vaccines Offer Hope for Fighting Malaria

A George Washington University-led team has developed mRNA vaccines for malaria that appear to provide protection in mice, as they report in NPJ Vaccines.

Unique Germline Variants Found Among Black Prostate Cancer Patients

Through an exome sequencing study appearing in JCO Precision Oncology, researchers have found unique pathogenic or likely pathogenic variants within a cohort of Black prostate cancer patients.